Introduction/Background To analyze the clinical outcomes and the safety of radiochemotherapy (RCT) and image-guided adaptive brachytherapy (IGABT) and to evaluate the impact of hysterectomy (HT) as completion of treatment for cervical cancer.
Methodology 145 patients with locally advanced cervical cancer were treated at our institution. Patients underwent RCT and IGABT, then hysterectomy (HT) as completion of treatment was performed, with the exception of patients with surgical contraindications, para aortic metastatic disease or patients who refused surgery. Clinical outcomes and morbidity were retrospectively reviewed in both groups. Local relapse free survival (LRFS), pelvic relapse free survival (PRFS) and overall survival (OS) were analysed.
Results Completion HT was performed in 90 (62.1%) patients. Complete histological response and microscopic disease were found in 77 patients (85.6%). Local relapse was observed in 14 patients (9.6%) without differences between completion HT group and the definitive RCT and IGABT group (Odds Ratio OR=1.73 [0.57–5.23], p=0.33). The estimated 3-year LRFS and PRFS for the entire population were respectively 90% [84%-94%] and 93% [87%-96%], with no significant differences between them (respectively Hazard Ratio HR=0.57 [0.20–1.64], p=0.30 and HR=0.37 [0.10–1.31], p=0.12). The estimated 3-year OS rate for the whole population was 84% [75%-91%] with no significant differences between groups (HR=0.81 [0.32–2.06], p=0.65). Regarding morbidity, grade ≥2 vaginal toxicity was more frequent in the definitive RCT and IGABT group (43.6% vs 26.7%, p=0.04). All grade 4 toxicity events were reported in the completion HT group.
Conclusion Due to high severe toxicity, RCT and IGABT with dose escalation followed by completion hysterectomy don’t seem compatible. No benefit and increased severe late morbidity were observed. Combined intracavitary/interstitial technique is mandatory in large target volume at brachytherapy.
Disclosures All authors declare no conflict of interest.
There was no founding source for this study.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.